The proline-rich tetramerization peptides in equine serum butyrylcholinesterase

FEBS Journal

Volumn 279, Issue 20, 2012, Pages 3844-3858

  Biberoglu, Kevser ^a   Schopfer, Lawrence M ^b   Tacal, Ozden ^a   Lockridge, Oksana ^b  

^a HACETTEPE UNIVERSITY   (Turkey)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

mass spectrometry; polyproline peptide; serum butyrylcholinesterase

Indexed keywords

CHOLINESTERASE; PEPTIDE; PROLINE RICH PEPTIDE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; ENZYME STRUCTURE; HORSE; ION TRAP MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; POLYMERIZATION; PRIORITY JOURNAL; TETRAMERIZATION;

AMINO ACID SEQUENCE; ANIMALS; BIOCATALYSIS; BUTYRYLCHOLINESTERASE; BUTYRYLTHIOCHOLINE; CARRIER PROTEINS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HORSES; HUMANS; HYDROLYSIS; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; PEPTIDES; PROLINE; PROTEIN MULTIMERIZATION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EQUIDAE;

EID: 84867103032     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2012.08744.x     Document Type: Article

References (36)

1. Brimijoin S, &, Gao Y, (2012) Cocaine hydrolase gene therapy for cocaine abuse. Future Med Chem 4, 151-162.
2. Saxena A, Sun W, Fedorko JM, Koplovitz I, &, Doctor BP, (2011) Prophylaxis with human serum butyrylcholinesterase protects guinea pigs exposed to multiple lethal doses of soman or vx. Biochem Pharmacol 81, 164-169.
3. Masson P, &, Lockridge O, (2010) Butyrylcholinesterase for protection from organophosphorus poisons: catalytic complexities and hysteretic behavior. Arch Biochem Biophys 494, 107-120.
4. Giacobini E, (2003) Butyrylcholinesterase its Function and Inhibitors. Martin Dunitz, Taylor & Francis Group, London.
5. Broomfield CA, Maxwell DM, Solana RP, Castro CA, Finger AV, &, Lenz DE, (1991) Protection by butyrylcholinesterase against organophosphorus poisoning in nonhuman primates. J Pharmacol Exp Ther 259, 633-638.
6. Darvesh S, Hopkins DA, &, Geula C, (2003) Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 4, 131-138.
7. Cohen JA, &, Warringa MG, (1954) The fate of p32 labelled diisopropylfluorophosphonate in the human body and its use as a labelling agent in the study of the turnover of blood plasma and red cells. J Clin Invest 33, 459-467.
8. Ostergaard D, Viby-Mogensen J, Hanel HK, &, Skovgaard LT, (1988) Half-life of plasma cholinesterase. Acta Anaesthesiol Scand 32, 266-269.
9. Saxena A, Raveh L, Ashani Y, &, Doctor BP, (1997) Structure of glycan moieties responsible for the extended circulatory life time of fetal bovine serum acetylcholinesterase and equine serum butyrylcholinesterase. Biochemistry 36, 7481-7489.
10. Chitlaru T, Kronman C, Velan B, &, Shafferman A, (2001) Effect of human acetylcholinesterase subunit assembly on its circulatory residence. Biochem J 354, 613-625.
11. Duysen EG, Bartels CF, &, Lockridge O, (2002) Wild-type and a328w mutant human butyrylcholinesterase tetramers expressed in chinese hamster ovary cells have a 16-hour half-life in the circulation and protect mice from cocaine toxicity. J Pharmacol Exp Ther 302, 751-758.
12. Saxena A, Ashani Y, Raveh L, Stevenson D, Patel T, &, Doctor BP, (1998) Role of oligosaccharides in the pharmacokinetics of tissue-derived and genetically engineered cholinesterases. Mol Pharmacol 53, 112-122.
13. Perrier AL, Massoulie J, &, Krejci E, (2002) PRiMA: the membrane anchor of acetylcholinesterase in the brain. Neuron 33, 275-285.
14. Bon S, Coussen F, &, Massoulie J, (1997) Quaternary associations of acetylcholinesterase. II. The polyproline attachment domain of the collagen tail. J Biol Chem 272, 3016-3021.
15. Dvir H, Harel M, Bon S, Liu WQ, Vidal M, Garbay C, Sussman JL, Massoulie J, &, Silman I, (2004) The synaptic acetylcholinesterase tetramer assembles around a polyproline II helix. EMBO J 23, 4394-4405.
16. Moorad DR, Luo C, Saxena A, Doctor BP, &, Garcia GE, (1999) Purification and determination of the amino acid sequence of equine serum butyrylcholinesterase. Toxicol Mech Methods 9, 219-227.
17. Wierdl M, Morton CL, Danks MK, &, Potter PM, (2000) Isolation and characterization of a cdna encoding a horse liver butyrylcholinesterase: evidence for cpt-11 drug activation. Biochem Pharmacol 59, 773-781.
18. Lockridge O, Bartels CF, Vaughan TA, Wong CK, Norton SE, &, Johnson LL, (1987) Complete amino acid sequence of human serum cholinesterase. J Biol Chem 262, 549-557.
19. Lockridge O, Adkins S, &, La DuBN, (1987) Location of disulfide bonds within the sequence of human serum cholinesterase. J Biol Chem 262, 12945-12952.
20. Nicolet Y, Lockridge O, Masson P, Fontecilla-Camps JC, &, Nachon F, (2003) Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J Biol Chem 278, 41141-41147.
21. Blong RM, Bedows E, &, Lockridge O, (1997) Tetramerization domain of human butyrylcholinesterase is at the C-terminus. Biochem J 327, 747-757.
22. Altamirano CV, &, Lockridge O, (1999) Conserved aromatic residues of the C-terminus of human butyrylcholinesterase mediate the association of tetramers. Biochemistry 38, 13414-13422.
23. Li H, Schopfer LM, Masson P, &, Lockridge O, (2008) Lamellipodin proline rich peptides associated with native plasma butyrylcholinesterase tetramers. Biochem J 411, 425-432.
24. Unnithan AG, Myer MJ, Veale CJ, &, Danell AS, (2007) MS/MS of protonated polyproline peptides: the influence of N-terminal protonation on dissociation. J Am Soc Mass Spectrom 18, 2198-2203.
25. Renner D, &, Spiteller G, (1988) Linked scan investigation of peptide degradation initiated by liquid secondary ion mass spectrometry. Biomed Environ Mass Spectrom 15, 75-77.
26. Grese RP, Cerny RL, &, Gross ML, (1989) Metal ion-peptide interactions in the gas phase: a tandem mass spectrometry study of alkali metal cationized peptides. J Am Chem Soc 111, 2835-2842.
27. Teesch LM, &, Adams J, (1991) Fragmentation of gas-phase complexes between alkali metal ions and peptides: metal ion binding to carbonyl oxygens and other neutral functional groups. J Am Chem Soc 113, 812-820.
28. Lin T, &, Glish GL, (1998) C-terminal peptide sequencing via multistage mass spectrometry. Anal Chem 70, 5162-5165.
29. Barr JM, &, Van Stipdonk MJ, (2002) Multi-stage tandem mass spectrometry of metal cationized leucine enkephalin and leucine enkephalin amide. Rapid Commun Mass Spectrom 16, 566-578.
30. Tang XJ, Ens W, Standing KG, &, Westmore JB, (1988) Daughter ion mass spectra from cationized molecules of small oligopeptides in a reflecting time-of-flight mass spectrometer. Anal Chem 60, 1791-1799.
31. Ralston JS, Main AR, Kilpatrick BF, &, Chasson AL, (1983) Use of procainamide gels in the purification of human and horse serum cholinesterases. Biochem J 211, 243-250.
32. Parikh K, Duysen EG, Snow B, Jensen NS, Manne V, Lockridge O, &, Chilukuri N, (2011) Gene-delivered butyrylcholinesterase is prophylactic against the toxicity of chemical warfare nerve agents and organophosphorus compounds. J Pharmacol Exp Ther 337, 92-101.
33. Teng TL, Harpst JA, Lee JC, Zinn A, &, Carlson DM, (1976) Composition and molecular weights of butyrylcholinesterase from horse serum. Arch Biochem Biophys 176, 71-81.
34. Allwood DA, Dreyfus RW, Perera IK, &, Dyer PE, (1996) UV optical absorption of matrices used for matrix-assisted laser desorption/ionization. Rapid Commun Mass Spectrom 10, 1575-1578.
35. Ellman GL, Courtney KD, Andres V Jr, &, Featherstone RM, (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7, 88-95.
36. Karnovsky MJ, &, Roots L, (1964) A 'direct-coloring' thiocholine method for cholinesterases. J Histochem Cytochem 12, 219-221.